Atrial natriuretic factor in two kidney--two clip renovascular hypertension in the rat. 1998

A M Puyo, and G W Vega, and A Pellegrino de Iraldi, and L E Albornoz, and M I Rosón, and P Scaglia, and M M Celentano, and J P Corazza, and E L Palumbo, and B E Fernández, and I J de la Riva
Departmento de Ciencias Biológicas, Facultad de Farmacia y Bioquimica, UBA, Argentina.

Hig levels of circulating atrial natriuretic factor (ANF) have been reported in several physiopathologic conditions like hypertension, heart and renal failure, pregnancy and high sodium intake. Nevertheless, neither relationships with water-sodium space regulation nor the role of an ANF vascular relaxant effect have been yet defined. The aim of present experiments was to characterize the contribution of circulating ANF and its vascular relaxing effects in the two kidney-two clip (2K2C) experimental model of renovascular hypertension. Complementary, plasma metabolites nitrite/nitrate of nitric oxide (NO) was examined because of mediation for both (NO an ANF) through cGMP. Three results showed (two-four weeks after surgery): indirect systolic blood pressure (mmHg), 186 +/- 4 in HT and 122 +/- 1 in SH (p < 0.001); a significant increase of plasma ANF (fmol/ml) in HT (n = 7, 1221 +/- 253) vs. SH (n = 9, 476 +/- 82; p < 0.02). Nitrate/nitrite plasma concentrations (mumol/l) were mpt different between SH and. The relaxant effect of ANF (10(-9), 10(-8) and 10(-7) M) on phenylephrine (3,5 x 10(-6) M) contracted rings from HT rats was smaller than SH rats (10(-8) M, p < 0.05). Contractions to phorbol 12, 13-dibutyrate (seven weeks after surgery) were significantly higher in rings from HT rats (p < 0.001). We conclude: 1) in addition to decreased granularity in atrial myocardiocytes, high circulating values of ANF here described suggest an increased turnover of the peptide in 2K2C hypertensive rats; 2) lower significant vascular relaxant effects in HT rats would indicate down regulation of ANF receptors in this model; the latter would derive from high plasma ANF concentration and, tentatively, because of greater activity of protein kinase C in the vascular wall; 39 similar values of plasma nitrite/nitrate in SH and HT rats would indicate a comparable NO circulating availability in both groups.

UI MeSH Term Description Entries
D006978 Hypertension, Renovascular Hypertension due to RENAL ARTERY OBSTRUCTION or compression. Hypertension, Goldblatt,Goldblatt Syndrome,Goldblatt Hypertension,Renovascular Hypertension,Syndrome, Goldblatt
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D009131 Muscle, Smooth, Vascular The nonstriated involuntary muscle tissue of blood vessels. Vascular Smooth Muscle,Muscle, Vascular Smooth,Muscles, Vascular Smooth,Smooth Muscle, Vascular,Smooth Muscles, Vascular,Vascular Smooth Muscles
D009320 Atrial Natriuretic Factor A potent natriuretic and vasodilatory peptide or mixture of different-sized low molecular weight PEPTIDES derived from a common precursor and secreted mainly by the HEART ATRIUM. All these peptides share a sequence of about 20 AMINO ACIDS. ANF,ANP,Atrial Natriuretic Peptide,Atrial Natriuretic Peptides,Atriopeptins,Auriculin,Natriuretic Peptides, Atrial,ANF (1-126),ANF (1-28),ANF (99-126),ANF Precursors,ANP (1-126),ANP (1-28),ANP Prohormone (99-126),ANP-(99-126),Atrial Natriuretic Factor (1-126),Atrial Natriuretic Factor (1-28),Atrial Natriuretic Factor (99-126),Atrial Natriuretic Factor Precursors,Atrial Natriuretic Factor Prohormone,Atrial Natriuretic Peptide (1-126),Atrial Pronatriodilatin,Atriopeptigen,Atriopeptin (1-28),Atriopeptin (99-126),Atriopeptin 126,Atriopeptin Prohormone (1-126),Cardiodilatin (99-126),Cardiodilatin Precursor,Cardionatrin I,Cardionatrin IV,Prepro-ANP,Prepro-CDD-ANF,Prepro-Cardiodilatin-Atrial Natriuretic Factor,Pro-ANF,ProANF,Proatrial Natriuretic Factor,Pronatriodilatin,alpha ANP,alpha-ANP Dimer,alpha-Atrial Natriuretic Peptide,beta-ANP,beta-Atrial Natriuretic Peptide,gamma ANP (99-126),gamma-Atrial Natriuretic Peptide,Natriuretic Peptide, Atrial,Peptide, Atrial Natriuretic,Peptides, Atrial Natriuretic,Prepro ANP,Prepro CDD ANF,Prepro Cardiodilatin Atrial Natriuretic Factor,Pro ANF,alpha ANP Dimer,alpha Atrial Natriuretic Peptide,beta ANP,beta Atrial Natriuretic Peptide,gamma Atrial Natriuretic Peptide
D009566 Nitrates Inorganic or organic salts and esters of nitric acid. These compounds contain the NO3- radical. Nitrate
D009569 Nitric Oxide A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP. Endogenous Nitrate Vasodilator,Mononitrogen Monoxide,Nitric Oxide, Endothelium-Derived,Nitrogen Monoxide,Endothelium-Derived Nitric Oxide,Monoxide, Mononitrogen,Monoxide, Nitrogen,Nitrate Vasodilator, Endogenous,Nitric Oxide, Endothelium Derived,Oxide, Nitric,Vasodilator, Endogenous Nitrate
D009573 Nitrites Salts of nitrous acid or compounds containing the group NO2-. The inorganic nitrites of the type MNO2 (where M Nitrite
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

A M Puyo, and G W Vega, and A Pellegrino de Iraldi, and L E Albornoz, and M I Rosón, and P Scaglia, and M M Celentano, and J P Corazza, and E L Palumbo, and B E Fernández, and I J de la Riva
January 1980, Hypertension (Dallas, Tex. : 1979),
A M Puyo, and G W Vega, and A Pellegrino de Iraldi, and L E Albornoz, and M I Rosón, and P Scaglia, and M M Celentano, and J P Corazza, and E L Palumbo, and B E Fernández, and I J de la Riva
July 1988, Journal of hypertension,
A M Puyo, and G W Vega, and A Pellegrino de Iraldi, and L E Albornoz, and M I Rosón, and P Scaglia, and M M Celentano, and J P Corazza, and E L Palumbo, and B E Fernández, and I J de la Riva
December 1987, The American journal of physiology,
A M Puyo, and G W Vega, and A Pellegrino de Iraldi, and L E Albornoz, and M I Rosón, and P Scaglia, and M M Celentano, and J P Corazza, and E L Palumbo, and B E Fernández, and I J de la Riva
January 1986, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
A M Puyo, and G W Vega, and A Pellegrino de Iraldi, and L E Albornoz, and M I Rosón, and P Scaglia, and M M Celentano, and J P Corazza, and E L Palumbo, and B E Fernández, and I J de la Riva
October 1985, Kidney international,
A M Puyo, and G W Vega, and A Pellegrino de Iraldi, and L E Albornoz, and M I Rosón, and P Scaglia, and M M Celentano, and J P Corazza, and E L Palumbo, and B E Fernández, and I J de la Riva
February 1987, Hypertension (Dallas, Tex. : 1979),
A M Puyo, and G W Vega, and A Pellegrino de Iraldi, and L E Albornoz, and M I Rosón, and P Scaglia, and M M Celentano, and J P Corazza, and E L Palumbo, and B E Fernández, and I J de la Riva
January 1997, Clinical and experimental hypertension (New York, N.Y. : 1993),
A M Puyo, and G W Vega, and A Pellegrino de Iraldi, and L E Albornoz, and M I Rosón, and P Scaglia, and M M Celentano, and J P Corazza, and E L Palumbo, and B E Fernández, and I J de la Riva
May 1987, British medical journal (Clinical research ed.),
A M Puyo, and G W Vega, and A Pellegrino de Iraldi, and L E Albornoz, and M I Rosón, and P Scaglia, and M M Celentano, and J P Corazza, and E L Palumbo, and B E Fernández, and I J de la Riva
April 2016, Life sciences,
A M Puyo, and G W Vega, and A Pellegrino de Iraldi, and L E Albornoz, and M I Rosón, and P Scaglia, and M M Celentano, and J P Corazza, and E L Palumbo, and B E Fernández, and I J de la Riva
January 2013, Biomedical reports,
Copied contents to your clipboard!